Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
t3

From: Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer

Table 3

Main adverse events classified according to the Common Terminology Criteria Adverse Events associated with MKIs and HS-TKIs treatment

Drug	Hypertension		Diarrhea		Skin rash		Anorexia		Nausea		Weight loss		Fatigue		QTc prolongation
Drug	Any grade	G3/4	Any gade	G3/4	Any grade	G3/4	Any grade	G3/4	Any grade	G3/4	Any grade	G3/4	Any grade	G3/4	Any grade	G3/4
Lenvatinib [5]	+++	++	+++	+	+	+	+++	+	++	+	++	+	+++	+	+	+
Sorafenib [6]	++	+	+++	+	+++	+	++	+	+	NE	++	+	++	+	NE	NE
Cabozantinib [36]	++	+	+++	+	+	+	++	+	++	+	++	+	++	+	NE	NE
Selpercatinib [41]	++	+	+++	+	+	+	+	+	+	+	+	+	+	+	NE	NE
Vandetanib [35]	++	+	+++	+	++	+	+	+	++	NE	+	NE	+	+	+	+
Pralsetinib [82]	+	+	+	+	NE	NE	NE	NE	NE	NE	NE	NE	+	+	NE	NE
Entrectinib [58]	NE	NE	++	+	+	NE	NE	NE	+	NE	NE	NE	++	+	NE	NE
Larotrectinib [13]	NE	NE	++	+	NE	NE	NE	NE	++	+	NE	NE	++	+	NE	NE
Dabrafenib + Trametinib [22]	+	+	+	NE	+	NE	+	NE	+++	+	NE	NE	+++	+	NE	NE

Return to article view

MKIs: multikinase inhibitors; HS-TKIs: highly selective tyrosine kinase inhibitors; QTc: QT interval corrected for heart rate; NE: no evidence; +: < 25%; ++: 25–50%; +++: 50–75%; ++++: > 75%